This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Ariad Pharma: The Contrarian Long Thesis

Iclusig may find use in other cancers and '113 is better than the market believes.

Cell Therapeutics: Addicted to Reverse Stock Splits

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

Programmed Insider Buying? Yes, at Insmed and United Therapeutics

Instead of selling stock whenever the wind blows, biotech execs should be buying.

Genta: 1998-2012
Genta: 1998-2012

10/25/12 - 07:00 AM EDT

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

How best to invest in the next important clinical trial catalyst facing Celgene.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs